Your browser doesn't support javascript.
loading
Systemic treatments in MDM2 positive intimal sarcoma: A multicentre experience with anthracycline, gemcitabine, and pazopanib within the World Sarcoma Network.
Frezza, Anna Maria; Assi, Tarek; Lo Vullo, Salvatore; Ben-Ami, Eytan; Dufresne, Armelle; Yonemori, Kan; Noguchi, Emi; Siontis, Brittany; Ferraro, Richard; Teterycz, Pawel; Duffaud, Florence; Ravi, Vinod; Vincenzi, Bruno; Gelderblom, Hans; Pantaleo, Maria A; Baldi, Giacomo G; Desar, Ingrid; Fedenko, Alexander; Maki, Robert G; Jones, Robin L; Benjamin, Robert S; Blay, Jean Yves; Kawai, Akira; Gounder, Mrinal; Gronchi, Alessandro; Le Cesne, Axel; Mir, Olivier; Czarnecka, Anna M; Schuetze, Scott; Wagner, Andrew J; Adam, Julien; Barisella, Marta; Sbaraglia, Marta; Hornick, Jason L; Meurgey, Alexandra; Mariani, Luigi; Casali, Paolo G; Thornton, Katherine; Stacchiotti, Silvia.
Afiliação
  • Frezza AM; Department of Medical Oncology, IRCCS Fondazione Istituto Nazionale Tumori, Milan, Italy.
  • Assi T; Department of Cancer Medicine, Gustave Roussy Cancer Campus, Villejuif, France.
  • Lo Vullo S; Unit of Clinical Epidemiology and Trial Organization, IRCCS Fondazione Istituto Nazionale Tumori, Milan, Italy.
  • Ben-Ami E; Center for Sarcoma and Bone Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Dufresne A; Department of Medical Oncology, Centre Léon Bérard & Université Claude Bernard Lyon I, Lyon, France.
  • Yonemori K; Department of Musculoskeletal Oncology, National Cancer Center Hospital, Tokyo, Japan.
  • Noguchi E; Department of Musculoskeletal Oncology, National Cancer Center Hospital, Tokyo, Japan.
  • Siontis B; Department of Medicine, University of Michigan, Ann Arbor, Michigan.
  • Ferraro R; Department of Medicine, Sarcoma Medical Oncology, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, New York.
  • Teterycz P; Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie Institute-Oncology Center, Warsaw, Poland.
  • Duffaud F; Department of Medical Oncology, La Timone University Hospital, Aix-Marseille Université, Marseille, France.
  • Ravi V; Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Vincenzi B; Department of Medical Oncology, Università Campus Bio-Medico di Roma, Rome, Italy.
  • Gelderblom H; Department of Medical Oncology, Leiden University Medical Center, Leiden, Netherlands.
  • Pantaleo MA; Department of Specialized, Experimental and Diagnostic Medicine, S. Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy.
  • Baldi GG; Department of Medical Oncology, Nuovo Ospedale "S. Stefano,", Prato, Italy.
  • Desar I; Department of Medical Oncology, Radboud University Medical Center, Nijmegen, the Netherlands.
  • Fedenko A; Department of Medical Oncology, N. N. Blokhin Russian Cancer Research, Moscow, Russian Federation.
  • Maki RG; Medical Oncology, Northwell Cancer Institute and Cold Spring Harbor Laboratory, Long Island, New York.
  • Jones RL; Sarcoma Unit, Royal Marsden NHS Foundation Trust/Institute of Cancer Research, London, United Kingdom.
  • Benjamin RS; Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Blay JY; Department of Medical Oncology, Centre Léon Bérard & Université Claude Bernard Lyon I, Lyon, France.
  • Kawai A; Department of Musculoskeletal Oncology, National Cancer Center Hospital, Tokyo, Japan.
  • Gounder M; Department of Medicine, Sarcoma Medical Oncology, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, New York.
  • Gronchi A; Sarcoma Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.
  • Le Cesne A; Department of Cancer Medicine, Gustave Roussy Cancer Campus, Villejuif, France.
  • Mir O; Department of Cancer Medicine, Gustave Roussy Cancer Campus, Villejuif, France.
  • Czarnecka AM; Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie Institute-Oncology Center, Warsaw, Poland.
  • Schuetze S; Department of Medicine, University of Michigan, Ann Arbor, Michigan.
  • Wagner AJ; Center for Sarcoma and Bone Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Adam J; Department of Pathology, Gustave Roussy Cancer Campus, Villejuif, France.
  • Barisella M; Department of Diagnostic Pathology and Laboratory Medicine, IRCCS Fondazione Istituto Nazionale dei Tumori, Milan, Italy.
  • Sbaraglia M; Department of Pathology, Treviso Regional Hospital, Italy.
  • Hornick JL; Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
  • Meurgey A; Department of Biopathology, Centre Léon Bérard, Lyon, France.
  • Mariani L; Unit of Clinical Epidemiology and Trial Organization, IRCCS Fondazione Istituto Nazionale Tumori, Milan, Italy.
  • Casali PG; Department of Medical Oncology, IRCCS Fondazione Istituto Nazionale Tumori, Milan, Italy.
  • Thornton K; Department of Oncology and Hemato-oncology, University of Milan, Milan, Italy.
  • Stacchiotti S; Center for Sarcoma and Bone Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Cancer ; 126(1): 98-104, 2020 01 01.
Article em En | MEDLINE | ID: mdl-31536651

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Sarcoma / Protocolos de Quimioterapia Combinada Antineoplásica / Túnica Íntima / Neoplasias Cardíacas Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Sarcoma / Protocolos de Quimioterapia Combinada Antineoplásica / Túnica Íntima / Neoplasias Cardíacas Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2020 Tipo de documento: Article